5 active not recruiting. 5 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Active not recruiting 5 |
| Phase 1 | 4 | Active not recruiting 4 |
Follow Severe Aplastic Anemia: new trials by email Literature Review of Severe Aplastic Anemia trials Research Report on Severe Aplastic Anemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure Ruxolitinib - Severe Aplastic Anemia, Single Lineage Cytopenias, T-LGL | Phase 1 / Phase 2 | Active not recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 13 | 2024-02-20 | 2026-10-14 |
| Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate - Acute Myeloid Leukemia in Remission, Adult Acute Lymphoblastic Leukemia in Complete Remission | Phase 1 / Phase 2 | Active not recruiting | Roswell Park Cancer Institute | 35 | 2017-08-09 | 2026-04-14 |
| Sirolimus (Rapamune ) for Relapse Prevention in People With Severe Aplastic Anemia Responsive to Immunosuppressive Therapy Sirolimus - Severe Aplastic Anemia | Phase 2 | Active not recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 84 | 2016-12-19 | 2026-10-06 |
| CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation CD34 Stem Cell Selection Therapy - Bone Marrow Failure Syndrome, Severe Aplastic Anemia | Phase 1 / Phase 2 | Active not recruiting | Diane George | 37 | 2013-03-01 | 2025-08-14 |
| Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia Cohort 1: hATG, CsA, EPAG Day 14 to Month 6, Cohort 2: hATG, CsA, EPAG Day 14 to Month 3, Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6 - Severe Aplastic Anemia | Phase 1 / Phase 2 | Active not recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 207 | 2012-07-02 | 2026-04-13 |
Anemia, Aplastic (5) · Acquired Immunodeficiency Syndrome (1) · Anemia, Diamond-Blackfan (1) · Anemia, Sickle Cell (1) · Autoimmune Diseases (1) · Bone Marrow Failure Disorders (1) · Graft vs Host Disease (1) · Hemoglobinopathies (1) · Histiocytosis (1) · Histiocytosis, Langerhans-Cell (1) · Hodgkin Disease (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Lymphohistiocytosis, Hemophagocytic (1) · Lymphoma, Non-Hodgkin (1) · Macrophage Activation Syndrome (1)
Anemia (5) · Bone Marrow Diseases (5) · Hematologic Diseases (5) · Hemic and Lymphatic Diseases (5) · Bone Marrow Failure Disorders (4) · Immune System Diseases (3) · Immunoproliferative Disorders (2) · Lymphatic Diseases (2) · Lymphoproliferative Disorders (2) · Anemia, Hemolytic (1) · Anemia, Hemolytic, Congenital (1) · Anemia, Hypoplastic, Congenital (1) · Blood Platelet Disorders (1) · Blood Protein Disorders (1) · Blood-Borne Infections (1)
Sirolimus (2) · Cyclophosphamide (1) · Cyclosporine (1) · Melphalan (1) · Mycophenolic Acid (1) · Whole-Body Irradiation (1) · eltrombopag (1) · fludarabine phosphate (1) · ruxolitinib (1)
National Heart, Lung, and Blood Institute (NHLBI) (3) · Diane George (1) · Roswell Park Cancer Institute (1)
United States (5)
Bhavisha A Patel, M.D. (1) · Bhavisha Patel, M.D. (1) · Diane George, MD (1) · Maureen Ross (1) · Neal S Young, M.D. (1)
PMID 26354756, PMID 29419434, PMID 29674506, PMID 29958797, PMID 33410523, PMID 33910334, PMID 34525188, PMID 34724566